Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.

ABSTRACT:

SUBMITTER: Chappell KJ 

PROVIDER: S-EPMC8055208 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature